These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Shaw C; Simms RJ; Pitcher D; Sandford R Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444 [TBL] [Abstract][Full Text] [Related]
9. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Merta M; Reiterová J; Tesar V; Stekrová J; Viklický O Ren Fail; 2002 Jul; 24(4):467-75. PubMed ID: 12212826 [TBL] [Abstract][Full Text] [Related]
11. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Merta M; Reiterová J; Tesar V; Stekrová J; Viklický O Ren Fail; 2002 Sep; 24(5):585-93. PubMed ID: 12380903 [TBL] [Abstract][Full Text] [Related]
12. Autosomal dominant polycystic kidney disease--more than a renal disease. Gabow PA Am J Kidney Dis; 1990 Nov; 16(5):403-13. PubMed ID: 2239929 [TBL] [Abstract][Full Text] [Related]
13. Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: a decision analysis. Butler WE; Barker FG; Crowell RM Neurosurgery; 1996 Mar; 38(3):506-15; discussion 515-6. PubMed ID: 8837803 [TBL] [Abstract][Full Text] [Related]
14. Management of end-stage autosomal dominant polycystic kidney disease with hemodialysis and transplantation. Mendelssohn DC; Harding ME; Cardella CJ; Cook GT; Uldall PR Clin Nephrol; 1988 Dec; 30(6):315-9. PubMed ID: 3072137 [TBL] [Abstract][Full Text] [Related]